{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T01:22:09Z","timestamp":1774142529077,"version":"3.50.1"},"reference-count":113,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["17\/148\/03"],"award-info":[{"award-number":["17\/148\/03"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Vaccination of infants with pneumococcal conjugate vaccines is recommended by the World Health Organization. Evidence is mixed regarding the differences in immunogenicity and efficacy of the different pneumococcal vaccines.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n The primary objective was to compare the immunogenicity of pneumococcal conjugate vaccine-10 versus pneumococcal conjugate vaccine-13. The main secondary objective was to compare the seroefficacy of pneumococcal conjugate vaccine-10 versus pneumococcal conjugate vaccine-13.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We searched the Cochrane Library, EMBASE, Global Health, MEDLINE, ClinicalTrials.gov and trialsearch.who.int up to July 2022. Studies were eligible if they directly compared either pneumococcal conjugate vaccine-7, pneumococcal conjugate vaccine-10 or pneumococcal conjugate vaccine-13 in randomised trials of children under 2 years of age, and provided immunogenicity data for at least one time point. Individual participant data were requested and aggregate data used otherwise.<\/jats:p>\n Outcomes included the geometric mean ratio of serotype-specific immunoglobulin G and the relative risk of seroinfection. Seroinfection was defined for each individual as a rise in antibody between the post-primary vaccination series time point and the booster dose, evidence of presumed subclinical infection.<\/jats:p>\n Each trial was analysed to obtain the log of the ratio of geometric means and its standard error. The relative risk of seroinfection (\u2018seroefficacy\u2019) was estimated by comparing the proportion of participants with seroinfection between vaccine groups.<\/jats:p>\n The log-geometric mean ratios, log-relative risks and their standard errors constituted the input data for evidence synthesis. For serotypes contained in all three vaccines, evidence could be synthesised using a network meta-analysis. For other serotypes, meta-analysis was used.<\/jats:p>\n Results from seroefficacy analyses were incorporated into a mathematical model of pneumococcal transmission dynamics to compare the differential impact of pneumococcal conjugate vaccine-10 and pneumococcal conjugate vaccine-13 introduction on invasive pneumococcal disease cases. The model estimated the impact of vaccine introduction over a 25-year time period and an economic evaluation was conducted.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 47 studies were eligible from 38 countries. Twenty-eight and 12 studies with data available were included in immunogenicity and seroefficacy analyses, respectively. Geometric mean ratios comparing pneumococcal conjugate vaccine-13 versus pneumococcal conjugate vaccine-10 favoured pneumococcal conjugate vaccine-13 for serotypes 4, 9V and 23F at 1 month after primary vaccination series, with 1.14- to 1.54-fold significantly higher immunoglobulin G responses with pneumococcal conjugate vaccine-13. Risk of seroinfection prior to the time of booster dose was lower for pneumococcal conjugate vaccine-13 for serotype 4, 6B, 9V, 18C and 23F than for pneumococcal conjugate vaccine-10. Significant heterogeneity and inconsistency were present for most serotypes and for both outcomes. Twofold higher antibody after primary vaccination was associated with a 54% decrease in risk of seroinfection (relative risk 0.46, 95% confidence interval 0.23 to 0.96).<\/jats:p>\n In modelled scenarios, pneumococcal conjugate vaccine-13 or pneumococcal conjugate vaccine-10 introduction in 2006 resulted in a reduction in cases that was less rapid for pneumococcal conjugate vaccine-10 than for pneumococcal conjugate vaccine-13. The pneumococcal conjugate vaccine-13 programme was predicted to avoid an additional 2808 (95% confidence interval 2690 to 2925) cases of invasive pneumococcal disease compared with pneumococcal conjugate vaccine-10 introduction between 2006 and 2030.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Analyses used data from infant vaccine studies with blood samples taken prior to a booster dose. The impact of extrapolating pre-booster efficacy to post-booster time points is unknown. Network meta-analysis models contained significant heterogeneity which may lead to bias.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Serotype-specific differences were found in immunogenicity and seroefficacy between pneumococcal conjugate vaccine-13 and pneumococcal conjugate vaccine-10. Higher antibody response after vaccination was associated with a lower risk of subsequent infection. These methods can be used to compare the pneumococcal conjugate vaccines and optimise vaccination strategies. For future work, seroefficacy estimates can be determined for other pneumococcal vaccines, which could contribute to licensing or policy decisions for new pneumococcal vaccines.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42019124580.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17\/148\/03) and is published in full in Health Technology Assessment; Vol. 28, No. 34. See the NIHR Funding and Awards website for further award information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/ywha3079","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T07:24:28Z","timestamp":1695194668000},"page":"1-109","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7855-0991","authenticated-orcid":true,"given":"Shuo","family":"Feng","sequence":"first","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-8631","authenticated-orcid":true,"given":"Julie","family":"McLellan","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6491-1159","authenticated-orcid":true,"given":"Nicola","family":"Pidduck","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1142-6440","authenticated-orcid":true,"given":"Nia","family":"Roberts","sequence":"additional","affiliation":[{"name":"Bodleian Health Care Libraries, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8323-2514","authenticated-orcid":true,"given":"Julian PT","family":"Higgins","sequence":"additional","affiliation":[{"name":"Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-4366","authenticated-orcid":true,"given":"Yoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Modelling and Economics Unit, UK Health Security Agency, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5547-7223","authenticated-orcid":true,"given":"Alane","family":"Izu","sequence":"additional","affiliation":[{"name":"South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-8255","authenticated-orcid":true,"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-0636","authenticated-orcid":true,"given":"Shabir A","family":"Madhi","sequence":"additional","affiliation":[{"name":"South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7947-680X","authenticated-orcid":true,"given":"Kim","family":"Mulholland","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-719X","authenticated-orcid":true,"given":"Andrew J","family":"Pollard","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0380-1503","authenticated-orcid":true,"given":"Simon","family":"Procter","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-9848","authenticated-orcid":true,"given":"Beth","family":"Temple","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6324-6559","authenticated-orcid":true,"given":"Merryn","family":"Voysey","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2024,7]]},"reference":[{"key":"key2024072416590700_ref1-bib1","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000\u201315","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"key2024072416590700_ref2-bib2","doi-asserted-by":"crossref","first-page":"e1000348","DOI":"10.1371\/journal.pmed.1000348","article-title":"Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project","volume":"7","author":"Johnson","year":"2010","journal-title":"PLOS Med"},{"key":"key2024072416590700_ref3-bib3","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","article-title":"Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis","volume":"5","author":"Shiri","year":"2017","journal-title":"Lancet Glob Health"},{"key":"key2024072416590700_ref4-bib4","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/21645515.2021.1874219","article-title":"Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL\u00ae)","volume":"17","author":"Alderson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"key2024072416590700_ref5-bib5","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"key2024072416590700_ref6-bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref7-bib7","doi-asserted-by":"crossref","first-page":"e20190377","DOI":"10.1542\/peds.2019-0377","article-title":"Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease","volume":"145","author":"Berman-Rosa","year":"2020","journal-title":"Pediatrics"},{"key":"key2024072416590700_ref8-bib8","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.vaccine.2021.02.043","article-title":"Effect of a 2\u2009+\u20091 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: results from a randomised controlled trial in Vietnam","volume":"39","author":"Temple","year":"2021","journal-title":"Vaccine"},{"key":"key2024072416590700_ref9-bib9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/cid\/ciy743","article-title":"Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomized controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean infants","volume":"68","author":"Pomat","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key2024072416590700_ref10-bib10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cix895","article-title":"Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries","volume":"66","author":"Voysey","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key2024072416590700_ref11-bib11","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"key2024072416590700_ref12-bib12","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"key2024072416590700_ref13-bib13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"key2024072416590700_ref14-bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Res Synth Methods"},{"key":"key2024072416590700_ref15-bib15","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-21416-0","volume-title":"Network Meta-Analysis. Meta-Analysis with R","author":"Schwarzer","year":"2015"},{"key":"key2024072416590700_ref16-bib16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2024072416590700_ref17-bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"key2024072416590700_ref18-bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/INF.0b013e31827b478d","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India","volume":"32","author":"Amdekar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref19-bib19","first-page":"e275","article-title":"Correction to Lancet Infect Dis","volume":"20","author":"Anonymous","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref20-bib20","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.vaccine.2021.03.032","article-title":"Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: a randomised controlled trial","volume":"39","author":"Beissbarth","year":"2021","journal-title":"Vaccine"},{"key":"key2024072416590700_ref21-bib21","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1097\/INF.0b013e318199f901","article-title":"The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV\/Hib and poliovirus vaccines: assessment of immunogenicity","volume":"28","author":"Bermal","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref22-bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/INF.0b013e3181f2da06","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV\/Hib and poliovirus vaccines","volume":"30","author":"Bermal","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref23-bib23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1542\/peds.2009-1405","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine","volume":"125","author":"Bryant","year":"2010","journal-title":"Pediatrics"},{"key":"key2024072416590700_ref24-bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2018.07.023","article-title":"Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: results from a phase II, randomised, multicentre study","volume":"37","author":"Carmona Martinez","year":"2019","journal-title":"Vaccine"},{"key":"key2024072416590700_ref25-bib25","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"key2024072416590700_ref26-bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/cid\/ciaa083","article-title":"Carrier-induced hyporesponsiveness to pneumococcal conjugate vaccines: unraveling the influence of serotypes, timing, and previous vaccine dose","volume":"72","author":"Dagan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key2024072416590700_ref27-bib27","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1016\/j.vaccine.2016.06.075","article-title":"Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration","volume":"34","author":"Dagan","year":"2016","journal-title":"Vaccine"},{"key":"key2024072416590700_ref28-bib28","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.vaccine.2016.12.052","article-title":"PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children","volume":"35","author":"Dagan","year":"2017","journal-title":"Vaccine"},{"key":"key2024072416590700_ref29-bib29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/infdis\/jiu576","article-title":"Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae","volume":"211","author":"Dagan","year":"2015","journal-title":"J Infect Dis"},{"key":"key2024072416590700_ref30-bib30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key2024072416590700_ref31-bib31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1128\/CVI.00062-10","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers","volume":"17","author":"Esposito","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key2024072416590700_ref32-bib32","doi-asserted-by":"crossref","first-page":"6042","DOI":"10.1016\/j.vaccine.2011.06.026","article-title":"Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine","volume":"29","author":"Gimenez-Sanchez","year":"2011","journal-title":"Vaccine"},{"key":"key2024072416590700_ref33-bib33","doi-asserted-by":"crossref","first-page":"9675","DOI":"10.1016\/j.vaccine.2011.10.012","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants","volume":"29","author":"Grimprel","year":"2011","journal-title":"Vaccine"},{"key":"key2024072416590700_ref34-bib34","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.vaccine.2011.12.054","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan","volume":"30","author":"Huang","year":"2012","journal-title":"Vaccine"},{"key":"key2024072416590700_ref35-bib35","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/CVI.00172-14","article-title":"Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization","volume":"21","author":"Juergens","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"key2024072416590700_ref36-bib36","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"key":"key2024072416590700_ref37-bib37","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/INF.0b013e31822a8541","article-title":"Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants","volume":"30","author":"Kim","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref38-bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/INF.0b013e3182748bb6","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines","volume":"32","author":"Kim","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref39-bib39","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/INF.0b013e3182323ac2","article-title":"Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants","volume":"31","author":"Knuf","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref40-bib40","doi-asserted-by":"crossref","first-page":"e007247","DOI":"10.1136\/bmjopen-2014-007247","article-title":"Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial","volume":"5","author":"Leach","year":"2015","journal-title":"BMJ Open"},{"key":"key2024072416590700_ref41-bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12887-021-02552-z","article-title":"Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial","volume":"21","author":"Leach","year":"2021","journal-title":"BMC Pediatr"},{"key":"key2024072416590700_ref42-bib42","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.jvacx.2021.100086","article-title":"Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial","volume":"7","author":"Leach","year":"2021","journal-title":"Vaccine X"},{"key":"key2024072416590700_ref43-bib43","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1473-3099(22)00272-9","article-title":"Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials","volume":"22","author":"Leach","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref44-bib44","first-page":"84","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines to infants in Korea","volume":"99","author":"Lee","year":"2010","journal-title":"Acta Paediatr Int J Paediatr"},{"key":"key2024072416590700_ref45-bib45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41479-017-0044-z","article-title":"Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea","volume":"9","author":"Lehmann","year":"2017","journal-title":"Pneumonia (Nathan)"},{"key":"key2024072416590700_ref46-bib46","first-page":"603","article-title":"Immunogenicity and memory B cell response following alternative pneumococcal vaccination strategies in Vietnam","volume":"46","author":"Licciardi","year":"2016","journal-title":"Eur J Immunol"},{"key":"key2024072416590700_ref47-bib47","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S1473-3099(20)30775-1","article-title":"Immunogenicity of alternative ten-valent pneumococcal conjugate vaccine schedules in infants in Ho Chi Minh City, Vietnam: results from a single-blind, parallel-group, open-label, randomised, controlled trial","volume":"21","author":"Licciardi","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref48-bib48","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1473-3099(20)30289-9","article-title":"Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial","volume":"20","author":"Madhi","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref49-bib49","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.vaccine.2017.03.071","article-title":"Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: a phase 2, randomized, controlled, observer-blind study","volume":"35","author":"Odutola","year":"2017","journal-title":"Vaccine"},{"key":"key2024072416590700_ref50-bib50","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1016\/j.vaccine.2019.03.033","article-title":"Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines: a phase II, randomised, observer-blind study in Gambian infants","volume":"37","author":"Odutola","year":"2019","journal-title":"Vaccine"},{"key":"key2024072416590700_ref51-bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/INF.0b013e3182906499","article-title":"Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States","volume":"32","author":"Payton","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref52-bib52","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/cid\/ciy743","article-title":"Safety and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: a randomised controlled trial of 10-valent and 13-valent PCV in Papua New Guinean infants","volume":"68","author":"Pomat","year":"2018","journal-title":"Clin Infect Dis"},{"key":"key2024072416590700_ref53-bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/ofid\/ofw172.606","article-title":"Immunogenicity of the booster dose of 2 investigational protein- based pneumococcal vaccine formulations in toddlers: a phase ii randomized trial","volume":"3","author":"Prymula","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key2024072416590700_ref54-bib54","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/ofid\/ofw172.608","article-title":"Safety and reactogenicity of the booster dose of 2 investigational protein-based pneumococcal vaccine formulations in toddlers: a phase II randomized trial","volume":"3","author":"Prymula","year":"2016","journal-title":"Open Forum Infect Disk"},{"key":"key2024072416590700_ref55-bib55","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1016\/j.vaccine.2017.07.008","article-title":"Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: results from a randomized phase II study in infants","volume":"35","author":"Prymula","year":"2017","journal-title":"Vaccine"},{"key":"key2024072416590700_ref56-bib56","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1097\/INF.0b013e3181faa6be","article-title":"Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref57-bib57","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(18)30734-5","article-title":"Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial","volume":"19","author":"Temple","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref58-bib58","doi-asserted-by":"crossref","first-page":"e019795","DOI":"10.1136\/bmjopen-2017-019795","article-title":"Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial","volume":"8","author":"Temple","year":"2018","journal-title":"BMJ Open"},{"key":"key2024072416590700_ref59-bib59","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0000000000000819","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with DTaP vaccine in healthy infants in Japan","volume":"34","author":"Togashi","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref60-bib60","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e31821a0614","article-title":"Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial","volume":"30","author":"van den Bergh","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref61-bib61","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1097\/INF.0000000000001170","article-title":"Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate baccine coadministered with DTPa-IPV-Hib in Dutch children: a randomized controlled trial","volume":"35","author":"van den Bergh","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref62-bib62","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1093\/cid\/cis922","article-title":"Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial","volume":"56","author":"van den Bergh","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key2024072416590700_ref63-bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/vaccines7010017","article-title":"Immunogenicity and immune memory after a pneumococcal polysaccharide vaccine booster in a high-risk population primed with 10-valent or 13-valent pneumococcal conjugate vaccine: a randomized controlled trial in Papua New Guinean children","volume":"7","author":"van den Biggelaar","year":"2019","journal-title":"Vaccines"},{"key":"key2024072416590700_ref64-bib64","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref65-bib65","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.1016\/j.vaccine.2012.10.040","article-title":"A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil","volume":"30","author":"Weckx","year":"2012","journal-title":"Vaccine"},{"key":"key2024072416590700_ref66-bib66","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines","volume":"28","author":"Wysocki","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref67-bib67","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"key2024072416590700_ref68-bib68","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/INF.0000000000002458","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine administered in a 3\u2009+\u20091 versus 2\u2009+\u20091 dose schedule among infants in China","volume":"38","author":"Zhu","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref69-bib69","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/INF.0000000000001248","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine compared with 7-valent pneumococcal conjugate vaccine among healthy infants in China","volume":"35","author":"Zhu","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref70-bib70","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1093\/ofid\/ofx163.1402","article-title":"Immunogenicity of a 2\u2009+\u20091 infant vaccination series with 13-valent pneumococcal conjugate vaccine (PCV13) followed by pneumococcal non-typeable Haemophilus influenzae protein d conjugate vaccine (PHID-CV): a randomized trial exploring interchangeability of PCVS","volume":"4","author":"De Los Santos","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"key2024072416590700_ref71-bib71","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1016\/j.vaccine.2013.06.049","article-title":"Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain","volume":"31","author":"Diez-Domingo","year":"2013","journal-title":"Vaccine"},{"key":"key2024072416590700_ref72-bib72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/INF.0b013e31824b972b","article-title":"13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety","volume":"31","author":"Martinon-Torres","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref73-bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/INF.0b013e318233049d","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada","volume":"31","author":"Vanderkooi","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref74-bib74","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/ofid\/ofab466.1367","article-title":"Phase 3 study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114 in healthy infants, children, and adolescents (PNEU-PLAN)","volume":"8","author":"Banniettis","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key2024072416590700_ref75-bib75","doi-asserted-by":"crossref","first-page":"S684","DOI":"10.1093\/ofid\/ofab466.1376","article-title":"A Phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114 and Prevnar 13TM with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)","volume":"8","author":"Bili","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"key2024072416590700_ref76-bib76","doi-asserted-by":"crossref","first-page":"e012488","DOI":"10.1136\/bmjopen-2016-012488","article-title":"Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China","volume":"6","author":"Chen","year":"2016","journal-title":"BMJ Open"},{"key":"key2024072416590700_ref77-bib77","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1473-3099(20)30735-0","article-title":"Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in the Gambia: a phase 3, randomised, double-blind, non-inferiority trial","volume":"21","author":"Clarke","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref78-bib78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.vaccine.2019.08.072","article-title":"Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in the Gambia: results of a phase 1\/2 randomized, double-blinded, controlled trial","volume":"38","author":"Clarke","year":"2020","journal-title":"Vaccine"},{"key":"key2024072416590700_ref79-bib79","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/infdis\/174.6.1271","article-title":"Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine","volume":"174","author":"Dagan","year":"1996","journal-title":"J Infect Dis"},{"key":"key2024072416590700_ref80-bib80","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1016\/j.vaccine.2018.02.113","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"36","author":"Greenberg","year":"2018","journal-title":"Vaccine"},{"key":"key2024072416590700_ref81-bib81","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1016\/j.vaccine.2018.05.027","article-title":"Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants: results from a double-blind randomized control trial Phase I","volume":"36","author":"Martinez","year":"2018","journal-title":"Vaccine"},{"key":"key2024072416590700_ref82-bib82","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/INF.0000000000002765","article-title":"A Phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in healthy infants","volume":"39","author":"Platt","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref83-bib83","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/21645515.2019.1568159","article-title":"A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants","volume":"15","author":"Rupp","year":"2019","journal-title":"Hum Vaccin Immunotherap"},{"key":"key2024072416590700_ref84-bib84","doi-asserted-by":"crossref","first-page":"S637","DOI":"10.1093\/ofid\/ofaa439.1421","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in healthy infants in the United States","volume":"7","author":"Senders","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"key2024072416590700_ref85-bib85","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/INF.0000000000003277","article-title":"Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States","volume":"40","author":"Senders","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"key2024072416590700_ref86-bib86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3345\/cep.2019.01067","article-title":"Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6\u201310 weeks: a randomized double-blind active-controlled trial","volume":"63","author":"Shin","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"key2024072416590700_ref87-bib87","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.4161\/hv.28642","article-title":"Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine","volume":"10","author":"Thisyakorn","year":"2014","journal-title":"Hum Vaccin Immunotherap"},{"key":"key2024072416590700_ref88-bib88","doi-asserted-by":"crossref","first-page":"870973","DOI":"10.3389\/fmicb.2022.870973","article-title":"Immunogenicity and safety of a novel 13-valent pneumococcal vaccine in healthy Chinese infants and toddlers","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Microbiol"},{"key":"key2024072416590700_ref89-bib89","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(22)00734-4","article-title":"Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2\u2009+\u20091 schedule to healthy infants in the Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial","volume":"23","author":"Adigweme","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key2024072416590700_ref90-bib90","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2022.10.072","article-title":"A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)","volume":"41","author":"Bili","year":"2023","journal-title":"Vaccine"},{"key":"key2024072416590700_ref91-bib91","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1016\/j.vaccine.2022.09.003","article-title":"A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, children, and adolescents (PNEU-PLAN)","volume":"40","author":"Banniettis","year":"2022","journal-title":"Vaccine"},{"key":"key2024072416590700_ref92-bib92","first-page":"A204","article-title":"A Phase 3, multicenter, randomised, doubleblind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of v114 in healthy infants (PNEU-PED)","volume":"107","author":"Lupinacci","year":"2022","journal-title":"Arch Dis Child"},{"key":"key2024072416590700_ref93-bib93","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.vaccine.2022.12.054","article-title":"A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)","volume":"41","author":"Lupinacci","year":"2023","journal-title":"Vaccine"},{"key":"key2024072416590700_ref94-bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-10-90","article-title":"Dynamic models of pneumococcal carriage and the impact of the heptavalent pneumococcal conjugate vaccine on invasive pneumococcal disease","volume":"10","author":"Melegaro","year":"2010","journal-title":"BMC Infect Dis"},{"key":"key2024072416590700_ref95-bib95","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1017\/S0950268805004012","article-title":"A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting","volume":"133","author":"Hussain","year":"2005","journal-title":"Epidemiol Infect"},{"key":"key2024072416590700_ref96-bib96","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLOS Med"},{"key":"key2024072416590700_ref97-bib97","doi-asserted-by":"crossref","first-page":"e76180","DOI":"10.1371\/journal.pone.0076180","article-title":"The social life of infants in the context of infectious disease transmission; social contacts and mixing patterns of the very young","volume":"8","author":"van Hoek","year":"2013","journal-title":"PLOS ONE"},{"key":"key2024072416590700_ref98-bib98","doi-asserted-by":"crossref","first-page":"e1002845","DOI":"10.1371\/journal.pmed.1002845","article-title":"Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2\u2009+\u20091 to 1\u2009+\u20091 in England and Wales: a modelling study","volume":"16","author":"Choi","year":"2019","journal-title":"PLOS Med"},{"key":"key2024072416590700_ref99-bib99","doi-asserted-by":"crossref","first-page":"e39927","DOI":"10.1371\/journal.pone.0039927","article-title":"Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales","volume":"7","author":"Choi","year":"2012","journal-title":"PLOS ONE"},{"key":"key2024072416590700_ref100-bib100","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1016\/j.vaccine.2012.10.017","article-title":"The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England","volume":"30","author":"van Hoek","year":"2012","journal-title":"Vaccine"},{"key":"key2024072416590700_ref101-bib101","volume-title":"Population Estimates for the UK, England and Wales, Scotland and Northern Ireland: Mid-2016","author":"Office for National Statistics","year":"2017"},{"key":"key2024072416590700_ref102-bib102","volume-title":"National Life Tables, UK","author":"Office for National Statistics"},{"key":"key2024072416590700_ref103-bib103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jinf.2010.04.008","article-title":"The risk of sequelae due to pneumococcal meningitis in high-income countries: a systematic review and meta-analysis","volume":"61","author":"Jit","year":"2010","journal-title":"J Infect"},{"key":"key2024072416590700_ref104-bib104","volume-title":"World Population Prospects 2022","author":"United Nations Department of Economic and Social Affairs"},{"key":"key2024072416590700_ref105-bib105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","article-title":"The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison","volume":"55","author":"Oostenbrink","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"key2024072416590700_ref106-bib106","volume-title":"Unit Costs of Health and Social Care 2009","author":"Curtis","year":"2009"},{"key":"key2024072416590700_ref107-bib107","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"key":"key2024072416590700_ref108-bib108","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1016\/j.vaccine.2016.06.038","article-title":"The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: a systematic review and meta-analysis of randomised controlled trials","volume":"34","author":"Voysey","year":"2016","journal-title":"Vaccine"},{"key":"key2024072416590700_ref109-bib109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2352-4642(18)30168-8","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study","volume":"2","author":"Pichichero","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"key":"key2024072416590700_ref110-bib110","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1016\/j.vaccine.2018.07.078","article-title":"How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country","volume":"36","author":"Casta\u00f1eda-Orjuela","year":"2018","journal-title":"Vaccine"},{"key":"key2024072416590700_ref111-bib111","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.vaccine.2011.04.111","article-title":"Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina","volume":"29","author":"Urue\u00f1a","year":"2011","journal-title":"Vaccine"},{"key":"key2024072416590700_ref112-bib112","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.vaccine.2019.06.015","article-title":"An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand","volume":"37","author":"Dilokthornsakul","year":"2019","journal-title":"Vaccine"},{"key":"key2024072416590700_ref113-bib113","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1164\/rccm.201212-2277OC","article-title":"Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults","volume":"187","author":"Ferreira","year":"2013","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2045643","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/YWHA3079\/YWHA3079.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2045643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T07:46:05Z","timestamp":1721807165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/YWHA3079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":113,"alternative-id":["10.3310\/YWHA3079"],"URL":"https:\/\/doi.org\/10.3310\/ywha3079","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.13.23284388","asserted-by":"object"}]},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2019","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"04-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"09-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}